KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Change in Accured Expenses (2016 - 2025)

Acadia Pharmaceuticals has reported Change in Accured Expenses over the past 16 years, most recently at $5.2 million for Q4 2025.

  • Quarterly results put Change in Accured Expenses at $5.2 million for Q4 2025, down 82.95% from a year ago — trailing twelve months through Dec 2025 was $1.1 million (down 98.48% YoY), and the annual figure for FY2025 was $1.1 million, down 98.48%.
  • Change in Accured Expenses for Q4 2025 was $5.2 million at Acadia Pharmaceuticals, up from -$14.7 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for ACAD hit a ceiling of $54.9 million in Q3 2023 and a floor of -$49.0 million in Q4 2023.
  • Median Change in Accured Expenses over the past 5 years was $5.9 million (2022), compared with a mean of $4.7 million.
  • Biggest five-year swings in Change in Accured Expenses: skyrocketed 612.5% in 2022 and later tumbled 849.26% in 2023.
  • Acadia Pharmaceuticals' Change in Accured Expenses stood at $8.8 million in 2021, then fell by 25.78% to $6.5 million in 2022, then tumbled by 849.26% to -$49.0 million in 2023, then soared by 162.85% to $30.8 million in 2024, then plummeted by 82.95% to $5.2 million in 2025.
  • The last three reported values for Change in Accured Expenses were $5.2 million (Q4 2025), -$14.7 million (Q3 2025), and $8.6 million (Q2 2025) per Business Quant data.